Pacira Biosciences, INC Form 4 insider transactions

Pacira BioSciences' Chief Operating Officer, Daryl Gaugler, sold 500 shares of common stock at $12.86 per share under a pre-arranged Rule 10b5-1 trading plan.

Director Marcelo Bigal purchased 1,512 shares of Pacira BioSciences (PCRX) at $13.25 per share on August 16, 2024.

Director Laura Brege purchased 1,000 shares of Pacira BioSciences (PCRX) common stock at $12.81 per share on August 16, 2024.

Director Michael J. Yang of Pacira BioSciences, Inc. (PCRX) reported purchasing 2,000 shares of common stock at $12.90 per share on August 14, 2024.

Pacira BioSciences CEO Frank D. Lee purchased 8,264 shares of common stock at $12.1 per share on August 12, 2024.

Marcelo Bigal, a director of Pacira BioSciences, filed an amended Form 4 to correct a typographical error in the original filing related to share purchases.

Mark Froimson, a director of Pacira BioSciences, Inc., purchased 1,400 shares of common stock at a price of $11.58 per share on August 12, 2024.

Director Marcelo Bigal purchased 3,400 shares of Pacira BioSciences (PCRX) at a weighted average price of $12.01 on August 12, 2024, increasing his direct holdings to 8,630 shares.

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports the sale of shares to cover tax obligations and pursuant to a pre-arranged trading plan.

Pacira BioSciences' Chief Operating Officer, Daryl Gaugler, acquired shares of common stock through the company's employee stock purchase plan.

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports acquiring shares through an employee stock purchase plan, shares withheld for tax obligations, and sales under a pre-arranged 10b5-1 trading plan.

Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, reports acquisition of stock units and sale of common stock under a pre-arranged 10b5-1 trading plan.

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports selling shares and acquiring restricted stock units.

Director Christopher Christie reported acquiring restricted stock units and disposing of common stock in Pacira BioSciences, Inc. on June 12, 2024.

Director Marcelo Bigal acquired 5,230 shares of common stock and 12,179 stock options in Pacira BioSciences on June 12, 2024.

Charles A. Reinhart III, CFO of Pacira BioSciences, reports the acquisition of 12,220 restricted stock units on June 12, 2024.

Michael J. Yang, a director at Pacira BioSciences, acquired stock options and restricted stock units on June 12, 2024.

Director Abraham Ceesay acquired 5,230 shares of common stock and 12,179 stock options in Pacira BioSciences on June 12, 2024.

Chief Operating Officer of Pacira BioSciences, Daryl Gaugler, reports acquisition of restricted stock units and sale of common stock.

Director Mark Froimson reports acquisition of stock options and restricted stock units in Pacira BioSciences.

Director Alethia Young reports acquisition of Pacira BioSciences common stock and stock options.

Director Paul J. Hastings of Pacira BioSciences reports acquisition and disposal of common stock and stock options.

Kristen Williams, Chief Administrative Officer of Pacira BioSciences, reports the acquisition and disposal of company stock, including transactions made under a pre-arranged Rule 10b5-1 trading plan.

Director Laura Brege reports acquisition of stock options and restricted stock units in Pacira BioSciences.

Mark A. Kronenfeld, a director of Pacira BioSciences, acquired shares and stock options on June 12, 2024, according to a Form 4 filing with the SEC.

Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, disposed of 1,843 shares of common stock on June 3, 2024, to cover tax withholding obligations.

Charles A. Reinhart III, CFO of Pacira BioSciences, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of a restricted stock unit award.

Kristen Williams, Chief Administrative Officer of Pacira BioSciences, reports disposition of shares to cover tax obligations upon vesting of a restricted stock unit award.

Chief Operating Officer of Pacira BioSciences, Daryl Gaugler, reports a transaction involving common stock to cover tax withholding obligations.

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports the disposal of 1,615 shares to cover tax obligations upon vesting of a restricted stock unit award.